EXE-346 is under clinical development by ExeGi Pharma and currently in Phase II for Pouchitis. According to GlobalData, Phase II drugs for Pouchitis does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the EXE-346 LoA Report. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

EXE-346 overview

EXE-346 is under development for the treatment of pouchitis relapse (ileal pouch-anal anastomosis). The therapeutic candidate is a live biotherapeutic product (LBP) which contains a fixed-proportion of 8 strains of live probiotic gram positive, lactic acid bacteria. It is administered through oral route. 

ExeGi Pharma overview

ExeGi Pharmaceuticals LLC (ExeGi) is a biotechnology company that develops live biotherapeutic and probiotic medicines. The company provides lead product candidates visbiome, a medical food that delivers anti-inflammatory probiotic bacteria in high concentrations. It provides its products in various therapeutic areas such as dietary management of pouchitis, ulcerative colitis and irritable bowel syndrome, liver disease, and others. ExeGi also offers product development, clinical development, manufacturing and commercialization services. The company serves across the US. ExeGi is headquartered in Rockville, Maryland, the US.

For a complete picture of EXE-346’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.